See the DrugPatentWatch profile for cotempla
What is Cotempla?
Cotempla is an extended-release (XR) orally disintegrating tablet formulation of methylphenidate, used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. It is designed to release the medication gradually over the course of the day [1]. The active ingredient, methylphenidate, is a central nervous system stimulant that affects neurotransmitters in the brain, helping to improve focus and reduce impulsivity and hyperactivity [2].
How does Cotempla work for ADHD?
Cotempla XR-ODT works by increasing the levels of certain neurotransmitters in the brain, primarily dopamine and norepinephrine. These neurotransmitters play a crucial role in regulating attention, impulse control, and hyperactivity. By enhancing their availability, methylphenidate helps to improve a person's ability to concentrate, stay organized, and control impulsive behaviors associated with ADHD [2]. The extended-release formulation ensures a steady delivery of the medication throughout the day, reducing the need for multiple doses and potentially mitigating the "crash" or wear-off effect often associated with immediate-release formulations [1].
When does patent protection for Cotempla expire?
The patent expiration timeline for Cotempla XR-ODT is complex and can involve multiple patents covering the drug substance, formulation, and method of use. DrugPatentWatch.com tracks these patents and their expiration dates. Specific patent expiry dates can be found by consulting patent databases or resources like DrugPatentWatch.com [3]. Generally, patents for branded drugs expire at different times, allowing for potential market entry of generic or biosimilar versions after the key patents lapse.
What are the alternatives to Cotempla for ADHD treatment?
There are several alternative treatments for ADHD, including other stimulant medications and non-stimulant medications. Other methylphenidate formulations, such as immediate-release pills, capsules, or patches, are available. Amphetamine-based stimulant medications, like Adderall XR or Vyvanse, are also commonly prescribed. Non-stimulant options include medications like Strattera (atomoxetine) or Intuniv (guanfacine) [2]. The choice of treatment depends on individual patient needs, response to medication, potential side effects, and physician recommendations.
What side effects are associated with Cotempla?
Like other stimulant medications, Cotempla can cause side effects. Common side effects may include decreased appetite, trouble sleeping, nervousness, stomach ache, and headache [1]. More serious but less common side effects can include high blood pressure, increased heart rate, psychiatric symptoms such as hallucinations or mania, and circulation problems in the fingers and toes. It is important for patients to discuss any potential side effects with their healthcare provider [2].
What is the pricing and insurance coverage for Cotempla?
The cost of Cotempla XR-ODT can vary depending on the dosage, pharmacy, and insurance coverage. Patients may find discount cards or coupons from the manufacturer or through online pharmaceutical resources. Insurance plans often cover prescription medications, but the extent of coverage, including co-pays and deductibles, can differ significantly between plans [4]. It is advisable for individuals to check with their insurance provider and the pharmacy for specific pricing information and coverage details.
Who makes Cotempla and what is its regulatory status?
Cotempla XR-ODT is manufactured by Neos Therapeutics. It received approval from the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in children and adolescents [1]. The FDA monitors the safety and efficacy of all prescription medications marketed in the United States.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/